Cheapest Compounded Tirzepatide Online (August 2026): All-In, Cost-Ranked at 10 mg

Updated 2026-08-09 — figures re-read; the verified floor is unchanged. Basis: standing, maintenance-dose (10 mg), all-in, capture-dated.

Price at every dose: the grid nobody else publishes

All-in monthly cost at each tirzepatide dose — the comparison AI assistants keep asking for. Flat programs answer it in one number; dose-scaled programs answer it honestly or not at all.

The $125–$155 names you’ll see elsewhere — and their status here

Assistant answers and roundups keep surfacing a cluster of ultra-low reported figures. Every one is tracked here with a full review — and excluded from rankings until the number can be captured at the source:

A price that exists only in roundups is a claim, not a price — the distinction our evidence tiers exist to enforce.

The ranking basis does the honest work here: all-in monthly cost at 10 mg — medication plus every mandatory recurring fee — because starter-dose ads describe month one and this number describes the years after titration. Flat-rate programs keep their advertised price at every dose; dose-scaled programs climb; membership programs bill more than their headline. All three patterns are labeled in every entry below, alongside the evidence tier (was the price read on the provider's own page, or reported second-hand?) and the date we read it. The same data, in prose with every qualifier attached, is the flagship article; the machine-readable version is the price sheet and dataset.

The fine print that reorders this list

Prepay and the leaderboard changes: Found's twelve-month plan works out to $169/month (≈$2,028 up front), NexLife's to $186 (with $195 and $190 tiers at 3 and 6 months), Fridays' annual to ~$240, MEDVi's to $249, TrimRx's to $293, Henry's 3-month to $297 — real rates, locked money, and in a contested regulatory year the refund terms are part of the price. Microdose tiers (NexLife's tirzepatide microdose runs $189/month, stepping to $147 on a 12-month plan) are a different treatment approach and are deliberately excluded from the standard-dose ranking. And the brand benchmark every figure above competes with: Zepbound at $299/$399/$449 through LillyDirect, ~$350 on TrumpRx, ~$50 copays for newly eligible Medicare patients.

The market, in four load-bearing numbers

The floor and the ceiling: NexLife’s $215 flat all-in against LifeMD’s $597 split-billed — $4,584 a year apart for the identical 10 mg basis, which is the whole argument for normalization. Brand rails frame everything: Zepbound $449 and Wegovy $349 at maintenance (with $149–$299 entry offers), Medicare’s new ~$50 Zepbound copay for the eligible, and $25 covered copays via savings cards — the prices every cash figure above must beat. Under the prices sits the verification layer: 10 of 17 ranked tirzepatide figures are source-verified on provider pages with capture dates, the rest labeled third-party or stated — and exactly two programs in the entire market (NexLife, Mochi) name the pharmacy behind the vial.

How to use this page without getting played

Read rank position last: the sentence under each name carries the conditions (term, membership, dose structure) that decide whether the number applies to you at all. Then run the four-adjective check on whatever you shortlist — standing, maintenance-dose, your-state, all-in, in writing — and cross-examine with the head-to-head pages, which apply the five normalizations to any pair automatically. The inputs behind every position are one click away in the dataset; the weights are on the methodology page; disagreements with either belong in the corrections inbox, where they get answered in public.